These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33650100)

  • 21. Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.
    O'Donnell E; Mo C; Yee AJ; Nadeem O; Laubach J; Rosenblatt J; Munshi N; Midha S; Cirstea D; Chrysafi P; Horick N; Richardson PG; Raje N
    Lancet Haematol; 2024 Jun; 11(6):e415-e424. PubMed ID: 38677302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
    Forsberg PA; Rossi AC; Boyer A; Tegnestam L; Pearse RN; Perry A; Pekle KA; Jayabalan D; Ely S; Boussi L; Sherbenou DW; Williams C; Allan JN; Coleman M; Niesvizky R; Mark TM
    Am J Hematol; 2019 May; 94(5):539-545. PubMed ID: 30740766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
    Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
    Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
    Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK
    Yong KL; Hinsley S; Auner HW; Bygrave C; Kaiser MF; Ramasamy K; De Tute RM; Sherratt D; Flanagan L; Garg M; Hawkins S; Williams C; Cavenagh J; Rabin NK; Croft J; Morgan G; Davies F; Owen RG; Brown SR
    Haematologica; 2021 Oct; 106(10):2694-2706. PubMed ID: 33910333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
    Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
    Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.
    Gregersen H; Peceliunas V; Remes K; Schjesvold F; Abildgaard N; Nahi H; Andersen NF; Vangsted AJ; Klausen TW; Helleberg C; Carlson K; Frølund UC; Axelsson P; Stromberg O; Blimark CH; Crafoord J; Tsykunova G; Eshoj HR; Waage A; Hansson M; Gulbrandsen N
    Eur J Haematol; 2022 Jan; 108(1):34-44. PubMed ID: 34536308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
    Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
    J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.
    Fang W; Sun W; Fang W; Zhao S; Wang C
    Int Immunopharmacol; 2024 Jun; 134():112178. PubMed ID: 38728883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
    Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M
    Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
    Monteith BE; Venner CP; Cheung MC; Pater J; Shepherd L; Richardson H; Reece D; Gul E; Lalancette M; Castonguay V; Kukreti V; Tiedemann R; Phua C; Bhella S; Dudebout J; Sherry M; Yen H; Chen BE; Hay AE
    Eur J Haematol; 2021 Sep; 107(3):333-342. PubMed ID: 34053112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review.
    Terao T; Tsushima T; Miura D; Ikeda D; Fukumoto A; Kuzume A; Tabata R; Narita K; Takeuchi M; Matsue K
    Leuk Lymphoma; 2022 May; 63(5):1102-1110. PubMed ID: 35373680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Multiple extramedullary plasmacytomas responding to a reduced dose of carfilzomib following drug-induced thrombotic microangiopathy].
    Fujimori C; Hagino T; Osanai S; Sano S; Saga R; Hidai H; Kurimoto M; Murai Y; Akiyama H; Motomura S
    Rinsho Ketsueki; 2022; 63(12):1626-1632. PubMed ID: 36653134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-weekly
    Bringhen S; Mina R; Petrucci MT; Gaidano G; Ballanti S; Musto P; Offidani M; Spada S; Benevolo G; Ponticelli E; Galieni P; Cavo M; Di Toritto TC; Di Raimondo F; Montefusco V; Palumbo A; Boccadoro M; Larocca A
    Haematologica; 2019 Aug; 104(8):1640-1647. PubMed ID: 30733270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.
    Ailawadhi S; Sexton R; Lentzsch S; Abidi MH; Voorhees PM; Cohen AD; Rohren EM; Heitner S; Kelly K; Mackler NJ; Baer DM; Hoering A; Durie B; Orlowski RZ
    Clin Cancer Res; 2020 Aug; 26(15):3969-3978. PubMed ID: 32299820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
    Gasparetto C; Schiller GJ; Tuchman SA; Callander NS; Baljevic M; Lentzsch S; Rossi AC; Kotb R; White D; Bahlis NJ; Chen CI; Sutherland HJ; Madan S; LeBlanc R; Sebag M; Venner CP; Bensinger WI; Biran N; Ammu S; Ben-Shahar O; DeCastro A; Van Domelen D; Zhou T; Zhang C; Bentur OS; Shah J; Shacham S; Kauffman M; Lipe B
    Br J Cancer; 2022 Mar; 126(5):718-725. PubMed ID: 34802051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.
    Venner CP; LeBlanc R; Sandhu I; White D; Belch AR; Reece DE; Chen C; Dolan S; Lalancette M; Louzada M; Kew A; McCurdy A; Monteith B; Reiman T; McDonald G; Sherry M; Gul E; Chen BE; Hay AE
    Am J Hematol; 2021 May; 96(5):552-560. PubMed ID: 33650179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carfilzomib-induced thrombotic microangiopathy. A case report.
    Scheggi V; Merilli I; Cesaroni E; Alterini B
    J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.